STOCK TITAN

Theseus Pharmaceuticals Inc - THRX STOCK NEWS

Welcome to our dedicated news page for Theseus Pharmaceuticals (Ticker: THRX), a resource for investors and traders seeking the latest updates and insights on Theseus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theseus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theseus Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.35%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
Theseus Pharmaceuticals Inc

Nasdaq:THRX

THRX Rankings

THRX Stock Data

181.28M
14.26M
2.56%
84.08%
0.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About THRX

theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.